| Rules-Based Medicine (RBM), the world’s leading multiplexed biomarker testing company, provides comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. RBM’s biomarker testing service, which is CLIA certified and supports GLP studies, provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins in a cost-effective manner, from a small sample volume and from multiple species. RBM also performs custom assay development, participates in co-sponsored research programs, pursues in-licensing of novel high-value assays and, through its wholly owned subsidiary EDI GmbH, provides Human Organotypic (HOT) cell culture systems. RBM combines EDI’s HOT systems with its HumanMAP® biomarker testing services to provide researchers with an unprecedented view of the physiological and biochemical impact of a new drug compound or consumer product prior to testing in a human subject. |
